The category is a mix, not a monolith
"Regenerative" is a loose umbrella stretched over treatments with very different levels of establishment. At one end sit approaches with a long track record and well-understood handling — platelet-rich fibrin and platelet-rich plasma drawn and processed from the patient's own blood. In the middle are polynucleotide-based boosters generating real demand and real questions. At the other end are exosome-related products surrounded by intense marketing and significant, unresolved regulatory questions in the US. Treating all of this as one trend — "we should offer regenerative" — is the first mistake, because the category's clinical maturity and regulatory footing vary enormously from one treatment to the next.
The demand trap
The dangerous dynamic in regenerative is that demand outruns regulatory clarity, and demand is loud. Patients see it on social media and ask for it by name. Competitors advertise it. Reps pitch it. All of that pressure pushes toward "if they want it and others offer it, we should too" — and that reasoning skips the only question that matters legally: can you actually source and offer this product, the way you intend to, on solid regulatory footing? The popularity of a treatment and the legality of a given product or claim are different things, and conflating them is how an owner ends up exposed on a treatment they adopted because the market seemed to demand it.
Exosomes are the sharpest example: an area of heavy marketing where the regulatory status is a serious, evolving question, and where what's being promoted and what's clearly permitted can diverge. The right posture there isn't reflexive yes or reflexive no — it's genuine regulatory diligence before anything else.
Separate defensible from trendy
The owner's framework is to sort the category by defensibility, not by buzz. The established, well-understood treatments with clear sourcing and footing can be built into a line with confidence. The newer, regulatorily uncertain ones require real diligence — on the product's regulatory status, on sourcing, on what you can and can't claim — before they belong anywhere near your menu, and some of them may not survive that diligence in a form you'd want to offer. Resisting the pressure to add something simply because it's trending or a competitor offers it is not timidity; it's the discipline that keeps a trendy category from becoming a regulatory liability with your name on it.
Why this is an owner's call
Injectors are drawn to new modalities, patients are drawn to new promises, and reps are paid to accelerate both. None of those parties owns the regulatory and liability exposure — you do. That's why the regenerative wave is an owner's decision before it's a clinical one: the question of whether you can and should offer a given regenerative treatment, on what footing, with what sourcing and what claims, sits above the question of whether it works or whether patients want it. Get the owner-level questions right and the clinical adoption can follow safely. Skip them, and clinical enthusiasm carries you straight into the landmines.
What to do
- Stop treating "regenerative" as one decision. Evaluate each treatment separately on clinical maturity and regulatory footing.
- Run real regulatory and sourcing diligence — with counsel — before building any line in the uncertain end of the category, exosomes especially.
- Don't let demand or competitor activity substitute for footing. Patients wanting it and others offering it doesn't make a product legally available to you as marketed.
- Build the defensible treatments with confidence and hold the trendy-but-uncertain ones to a higher bar, accepting that some won't clear it.
The regenerative wave is real, and parts of it represent genuine growth for practices that approach it well. But it's also the category where buzz, demand, and regulatory reality are most out of sync — and where the cost of letting enthusiasm outrun diligence is highest. Sort the real from the hyped and the defensible from the exposed, do the owner-level work before the clinical adoption, and you can ride the wave instead of being caught underneath it.
